Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta Sells 46,857 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 46,857 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $159,313.80. Following the completion of the sale, the chief executive officer now directly owns 418,637 shares in the company, valued at approximately $1,423,365.80. This represents a 10.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amit Gupta also recently made the following trade(s):

• On Friday, January 24th, Amit Gupta sold 15,160 shares of Cardlytics stock. The stock was sold at an average price of $3.92, for a total transaction of $59,427.20.
• On Friday, January 3rd, Amit Gupta sold 5,964 shares of Cardlytics stock. The shares were sold at an average price of $3.67, for a total value of $21,887.88.

Cardlytics Trading Down 7.4 %

Shares of Cardlytics stock opened at $3.12 on Thursday. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The business has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $3.72. Cardlytics, Inc. has a 1 year low of $2.76 and a 1 year high of $20.52. The company has a market capitalization of $158.56 million, a price-to-earnings ratio of -0.51 and a beta of 1.54.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the company. According to MarketBeat, Cardlytics currently has a consensus rating of “Hold” and an average price target of $6.92.

Institutional Trading of Cardlytics

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Cardlytics in the 3rd quarter valued at about $45,000. Creative Planning boosted its holdings in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after acquiring an additional 7,721 shares during the period. Acorn Financial Advisory Services Inc. ADV boosted its holdings in shares of Cardlytics by 40.5% during the third quarter. Acorn Financial Advisory Services Inc. ADV now owns 164,409 shares of the company’s stock worth $526,000 after acquiring an additional 47,358 shares during the period. GSA Capital Partners LLP grew its position in shares of Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the last quarter. Finally, Brooktree Capital Management increased its stake in shares of Cardlytics by 24.7% during the third quarter. Brooktree Capital Management now owns 167,642 shares of the company’s stock worth $536,000 after purchasing an additional 33,169 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.